<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Barrons</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">22 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.barrons.com/articles/liquidia-stock-patent-settlement-united-therapeutics-89c378ee">This Biotech Stock Surges 37% on Patent Settlement. ‘Better Than the Best-Case Scenario.</a>
    </div>

      <div class="me-0 me-md-5">
        Liquidia surges after reaching a $380.7 million settlement with United Therapeutics resolving patent disputes for its lung disease drug.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">22 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/technology/liquidia-stock-united-therapeutics-settlement-yutrepia-tyvaso/">Liquidia And United Therapeutics Settle; But Only One Stock Skyrocketed</a>
    </div>

      <div class="me-0 me-md-5">
        Liquidia stock skyrocketed Wednesday on settlement deal with United Therapeutics that allows its drug to stay on the market.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">23 days ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20261013239954/en/United-Therapeutics-Presents-New-Data-at-the-CHEST-2026-Annual-Meeting/">United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting</a>
    </div>

      <div class="me-0 me-md-5">
        SILVER SPRING, Md. &amp; RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoe...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260930122219/en/United-Therapeutics-Corporation-Prevails-in-Patent-Litigation-Against-Liquidia/">United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia</a>
    </div>

      <div class="me-0 me-md-5">
        SILVER SPRING, Md. &amp; RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics&#39; patent covering the use of inhaled treprostinil to trea...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/liquidia-slumps-after-us-court-rules-united-therapeutics-patent-fight-2026-09-30/">Liquidia slumps after US court rules for United Therapeutics in patent fight</a>
    </div>

      <div class="me-0 me-md-5">
        Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by ​rival United Therapeutics , dealing a major blow to the treatment&#39;s ‌commercial outlook.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about one month ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/technology/united-therapeutics-stock-liquidia-stock-yutrepia-tyvaso/">United Just Pulled The Ultimate Bull Move, As Its Chief Rival Collapsed</a>
    </div>

      <div class="me-0 me-md-5">
        A district judge ruled Wednesday that Liquidia infringed on United Therapeutics&#39; patents with its drug, Yutrepia. The stocks diverged.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">about 2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260908134529/en/United-Therapeutics-Corporation-Announces-Accelerated-Share-Repurchase-Agreement-for-Remainder-of-2.0-Billion-Authorization/">United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization</a>
    </div>

      <div class="me-0 me-md-5">
        SILVER SPRING, Md. &amp; RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the remainder of its previously announced $2 billion share repurchase authorization. To complete the utilization, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement w...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/United-Therapeutics-Corporation-US91307C1027">United Therapeutics Corporation</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">2 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260902138059/en/United-Therapeutics-Corporation-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-Nebulized-Tyvaso%C2%AE-to-Treat-Idiopathic-Pulmonary-Fibrosis/">United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis</a>
    </div>

      <div class="me-0 me-md-5">
        SILVER SPRING, Md. &amp; RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the supplemental New Drug Application (sNDA) for nebulized Tyvaso® (treprostinil) Inhalation Solution to treat IPF. United Therapeutics anticipates the agency&#39;s review to be complete in late April 2027. Nebuli...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/United-Therapeutics-Corporation-US91307C1027/load_more?page=3">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>